Lifordi Immunotherapeutics, Inc. will present additional preclinical data on its lead candidate LFD-200 at the upcoming American College of Rheumatology Convergence 2025 meeting. The antibody drug conjugate delivers a potent glucocorticoid directly to immune cells, with results from multiple in vitro and in vivo studies in non-human primates demonstrating that LFD-200 achieves targeted and sustained delivery of its glucocorticoid payload to immune cells without concurrent safety signals. This provides the efficacy of steroids without systemic toxicity, addressing a critical limitation of current autoimmune disease treatments.
The new non-human primate study data showed that LFD-200 provides targeted and sustained anti-inflammatory effects and a favorable safety profile at clinically relevant doses. Specifically, LFD-200 selectively delivered glucocorticoid to immune tissues and resulted in inhibition of ex vivo induced inflammatory cytokines with no observed systemic toxicity. These findings build upon prior studies and suggest LFD-200 has the potential to provide a safer, less frequently dosed glucocorticoid treatment option for patients living with autoimmune and inflammatory diseases. The company is developing antibody drug conjugates for the treatment of autoimmune and inflammatory disorders, with LFD-200 currently in a Phase 1 clinical trial.
The data presentation will occur during the Rheumatoid Arthritis – Treatment Poster I session on Sunday, October 26, 2025, from 10:30 AM to 12:30 PM. The poster is titled "LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates." The company has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein. For more information about the company's research and development efforts, visit https://www.lifordi.com.
The implications of these findings are significant for the autoimmune disease treatment landscape, as current glucocorticoid therapies often carry substantial side effects due to systemic exposure. The selective delivery approach demonstrated by LFD-200 could represent a major advancement in managing chronic inflammatory conditions while minimizing the toxicities that often limit long-term steroid use in patients with autoimmune disorders. This development matters because autoimmune diseases affect millions of people worldwide, and current treatments frequently involve balancing therapeutic benefits against serious side effects that can include weight gain, osteoporosis, diabetes, and increased infection risk. A targeted therapy that maintains efficacy while reducing systemic exposure could dramatically improve quality of life for patients requiring long-term immunosuppressive treatment.
